Kotani H - Search Results

1

Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.

Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Faramand R, et al. Among authors: kotani h. Clin Cancer Res. 2020 Sep 15;26(18):4823-4831. doi: 10.1158/1078-0432.CCR-20-1434. Epub 2020 Jul 15. Clin Cancer Res. 2020. PMID: 32669372 Free PMC article. Clinical Trial.

2

CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.

Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML. Boucher JC, et al. Among authors: kotani h. Cancer Immunol Res. 2021 Jan;9(1):62-74. doi: 10.1158/2326-6066.CIR-20-0253. Epub 2020 Nov 13. Cancer Immunol Res. 2021. PMID: 33188139 Free PMC article.

3

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.

Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. Roselli E, et al. Among authors: kotani h. J Immunother Cancer. 2021 Oct;9(10):e003354. doi: 10.1136/jitc-2021-003354. J Immunother Cancer. 2021. PMID: 34706886 Free PMC article.

4

Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.

Hashmi H, Bachmeier C, Chavez JC, Song J, Hussaini M, Krivenko G, Nishihori T, Kotani H, Davila ML, Locke FL, Jain MD. Hashmi H, et al. Among authors: kotani h. Br J Haematol. 2019 Oct;187(2):e35-e38. doi: 10.1111/bjh.16155. Epub 2019 Aug 13. Br J Haematol. 2019. PMID: 31410842 Free article. No abstract available.

5

4-1BB enhancement of CAR T function requires NF-κB and TRAFs.

Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, Wang X, Guan L, Beatty N, Abate-Daga D, Davila ML. Li G, et al. Among authors: kotani h. JCI Insight. 2018 Sep 20;3(18):e121322. doi: 10.1172/jci.insight.121322. eCollection 2018 Sep 20. JCI Insight. 2018. PMID: 30232281 Free PMC article.

6

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.

Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S. Suzuki C, et al. Among authors: kotani h. Cancer Sci. 2022 Jul;113(7):2323-2335. doi: 10.1111/cas.15354. Epub 2022 May 11. Cancer Sci. 2022. PMID: 35363931 Free PMC article.

7

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.

Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S. Kitai H, et al. Among authors: kotani h. Cancer Discov. 2016 Jul;6(7):754-69. doi: 10.1158/2159-8290.CD-15-1377. Epub 2016 May 6. Cancer Discov. 2016. PMID: 27154822 Free PMC article.

8

Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases.

Ohtsubo K, Miyake K, Arai S, Fukuda K, Suzuki C, Kotani H, Tanimoto A, Nishiyama A, Nanjo S, Yamashita K, Takeuchi S, Yano S. Ohtsubo K, et al. Among authors: kotani h. Cancer Diagn Progn. 2022 May 3;2(3):378-383. doi: 10.21873/cdp.10120. eCollection 2022 May-Jun. Cancer Diagn Progn. 2022. PMID: 35530650 Free PMC article.

9

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.

Tanimoto A, Takeuchi S, Kotani H, Yamashita K, Yamada T, Ohtsubo K, Ebi H, Ikeda H, Yano S. Tanimoto A, et al. Among authors: kotani h. BMC Pulm Med. 2018 Dec 12;18(1):193. doi: 10.1186/s12890-018-0757-7. BMC Pulm Med. 2018. PMID: 30541518 Free PMC article.

10

Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.

Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, Inase N, Yano S, Ebi H. Adachi Y, et al. Among authors: kotani h. Carcinogenesis. 2017 Oct 26;38(11):1063-1072. doi: 10.1093/carcin/bgx091. Carcinogenesis. 2017. PMID: 28968756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

525 results

Search Page